Hospital Ourense, Ourense, Spain
Maria C Areses Manrique , Urbano Anido , Ihab Abdulkader , Luis Leon
Background: Development and progression of kidney cancer is the result of an imbalance in signals promoting and inhibiting cellular proliferation and apoptosis. The aim of this study is to analize the expression of some molecular regulators and correlate them with clinical outcome in renal carcinoma, in order to establish common prognostic biomarkers. Methods: Tissue sample was obtained from nephrectomized patients in our center between 1998 and 2003. Biopsies were taken from 150 patients; a tissue array was done to analyze immunoexpression of proteins related to proliferation, cell cycle control and angiongenesis: p53, Ki 67, VEGF, VEGFR1, VEGFR2, HIF1, HIF2, cyclin D1, cyclin D3, cyclin B1, cyclin A, bcl2, p63, COX2, p16, p27, p21, EGFR, PDGF, PTEN, CAIX, BRAF, Akt and P13K. Subsequently the results were correlated with clinical variables (age, hypertension, smoking), pathological (tumor size, stage, Fuhrman grade) and time to progression and overall survival. Results: 92.3% of patients underwent nephrectomy, 11% associated with lymphadenectomy. Histology: 66.6% clear cell his, 14.1% papillary, chromophobe 6.4% and 15% miscellaneous. Stage I 49.4%; II 17.9%; 14.7% III; IV 14.1%; 3.8% unknown. Of the 150 patients analyzed, 23% had a second tumor. Median time to progression was 90.5 months (95% CI 81.7 to 114.3). The median survival has not yet been reached. Results of tissue array analysis wil be presented in the meeting. Conclusions: Patients in this serie have a good prognosis, since most tumors are stage I and II. We will present data on the expression of factors related to proliferation, cell cycle control and angiogenesis.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Monica F Chen
2023 ASCO Annual Meeting
First Author: Akiko Tateishi
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Amit Mahipal
2023 ASCO Annual Meeting
First Author: Laurien Joanna Zeverijn